Home
CRSP
CRSP News

Latest CRISPR Therapeutics AG (CRSP) News on November 17, 2024

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Motley Fool

a day ago

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Where Will CRISPR Therapeutics Be in 3 Years?

Motley Fool

2 days ago

Where Will CRISPR Therapeutics Be in 3 Years?

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

GlobeNewswire

3 days ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029

Motley Fool

4 days ago

3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029

Elon Musk will be 'vitally important' in Trump admin: Cathie Wood

Yahoo Finance Video

9 days ago

Elon Musk will be 'vitally important' in Trump admin: Cathie Wood

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

9 days ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

GlobeNewswire

10 days ago

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St.

10 days ago

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Morningstar Research

11 days ago

Analyst Report: CRISPR Therapeutics AG

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

Zacks

11 days ago

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

Zacks

11 days ago

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

Zacks

12 days ago

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

MT Newswires

12 days ago

CRISPR Therapeutics' Q3 Net Loss Narrows

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire

12 days ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

3 Companies Building Tomorrow's Game-Changing Technologies

Motley Fool

12 days ago

3 Companies Building Tomorrow's Game-Changing Technologies

CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average

Zacks

13 days ago

CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average

Zacks

13 days ago

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers

Motley Fool

15 days ago

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers

Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?

Insider Monkey

18 days ago

Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

Zacks

20 days ago

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

The Ultimate Biotech Stock to Buy With $50 Right Now

Motley Fool

22 days ago

The Ultimate Biotech Stock to Buy With $50 Right Now

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks

23 days ago

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Zacks

24 days ago

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Zacks

24 days ago

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

a month ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks

a month ago

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

Zacks

a month ago

Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth

Simply Wall St.

a month ago

We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Motley Fool

a month ago

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?

Insider Monkey

a month ago

Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?

Why I Keep Buying These 14 Incredible Growth Stocks

Motley Fool

a month ago

Why I Keep Buying These 14 Incredible Growth Stocks

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors

Zacks

a month ago

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors

Is CRISPR Therapeutics Stock a Buy?

Motley Fool

a month ago

Is CRISPR Therapeutics Stock a Buy?

2 Biotech Stocks That Are Screaming Buys This Month

Motley Fool

a month ago

2 Biotech Stocks That Are Screaming Buys This Month

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

Zacks

a month ago

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

This Healthcare Growth Stock Could Be a Steal of a Deal Right Now

Motley Fool

a month ago

This Healthcare Growth Stock Could Be a Steal of a Deal Right Now

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Pharmaceutical Technology

a month ago

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

MT Newswires

a month ago

RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

Zacks

a month ago

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now

Quartz

2 months ago

Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now

These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer

Motley Fool

2 months ago

These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Zacks

2 months ago

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics (NASDAQ:CRSP) shareholders have endured a 59% loss from investing in the stock three years ago

Simply Wall St.

2 months ago

CRISPR Therapeutics (NASDAQ:CRSP) shareholders have endured a 59% loss from investing in the stock three years ago

3 Dirt Cheap Stocks to Buy Right Now

Motley Fool

2 months ago

3 Dirt Cheap Stocks to Buy Right Now

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks

2 months ago

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?

Motley Fool

2 months ago

Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Zacks

2 months ago

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

1 Biotech Stock Down 62% to Buy and Hold

Motley Fool

2 months ago

1 Biotech Stock Down 62% to Buy and Hold

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

Motley Fool

2 months ago

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

Zacks

2 months ago

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers

Insider Monkey

2 months ago

CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers

Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?

Motley Fool

2 months ago

Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

Zacks

2 months ago

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

3 Monster Biotech Stocks to Buy Before 2025

Motley Fool

2 months ago

3 Monster Biotech Stocks to Buy Before 2025

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

Motley Fool

3 months ago

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Zacks

3 months ago

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

MT Newswires

3 months ago

Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating

Got the Market Sell-Off Blues? Do These 3 Things Right Now

Motley Fool

3 months ago

Got the Market Sell-Off Blues? Do These 3 Things Right Now

Morningstar Research

3 months ago

Analyst Report: CRISPR Therapeutics AG

MT Newswires

3 months ago

Morgan Stanley Cuts Price Target on CRISPR Therapeutics to $45 From $50, Keeps Underweight Rating

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

Zacks

3 months ago

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

MT Newswires

3 months ago

RBC Cuts Price Target on CRISPR Therapeutics to $60 From $66, Keeps Sector Perform, Speculative Risk

MT Newswires

3 months ago

Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

Zacks

3 months ago

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire

3 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker

Motley Fool

3 months ago

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker

MT Newswires

3 months ago

Rodman & Renshaw Initiates CRISPR Therapeutics at Buy With $90 Price Target

CRISPR Therapeutics AG (CRSP): Ark Invest is Bullish on This Stock Right Now

Insider Monkey

4 months ago

CRISPR Therapeutics AG (CRSP): Ark Invest is Bullish on This Stock Right Now

Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

4 months ago

Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

4 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Zacks

4 months ago

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

Zacks

4 months ago

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

Zacks

4 months ago

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

CRISPR Therapeutics Nears 52-Week Low. Time to Buy?

TipRanks

4 months ago

CRISPR Therapeutics Nears 52-Week Low. Time to Buy?

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

Zacks

4 months ago

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

Zacks

4 months ago

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

3 Monster Stocks in the Making to Buy Right Now

Motley Fool

4 months ago

3 Monster Stocks in the Making to Buy Right Now

Institutional investors must be pleased after a 8.9% gain last week that adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) one-year returns

Simply Wall St.

4 months ago

Institutional investors must be pleased after a 8.9% gain last week that adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) one-year returns

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

Zacks

4 months ago

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

Dow, S&P 500 rally on strong retail data, gold reaches record high: Yahoo Finance

Yahoo Finance Video

4 months ago

Dow, S&P 500 rally on strong retail data, gold reaches record high: Yahoo Finance

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Motley Fool

4 months ago

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

Motley Fool

4 months ago

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today

Zacks

4 months ago

Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today

Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?

Insider Monkey

5 months ago

Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?

Morningstar Research

5 months ago

Analyst Report: CRISPR Therapeutics AG

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."

Motley Fool

5 months ago

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?

Zacks

5 months ago

Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?

TipRanks

5 months ago

CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

Morningstar Research

5 months ago

Analyst Report: CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

5 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

5 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North

AFP

5 months ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

Simply Wall St.

5 months ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

5 months ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Simply Wall St.

5 months ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

5 months ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Share on Social Networks: